Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies designed to elicit individualized, systemic anti-tumor immune responses to help patients fight cancer. The company's website is www.candeltherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Candel Therapeutics, Inc. does
In the company’s own words
Candel Therapeutics, Inc. (NASDAQ: CADL) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies designed to elicit individualized, systemic anti-tumor immune responses to help patients fight cancer. The company's website is www.candeltherapeutics.com.
Candel's therapeutic approach centers on engineered viruses that induce immunogenic cell death within the tumor microenvironment, releasing tumor neo-antigens and creating a pro-inflammatory environment at injection sites. This mechanism is intended to generate in-situ immunization against injected tumors and uninjected distant metastases, potentially transforming immunologically "cold" tumors with limited immune response into "hot" tumors responsive to treatment.
The company operates two clinical viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Aglatimagene besadenovec, the most advanced product candidate, is a replication-defective adenovirus administered with the prodrug valacyclovir. In December 2024, Candel announced positive topline data from a pivotal phase 3 randomized, double-blind, placebo-controlled trial in newly diagnosed, localized prostate cancer with intermediate- to high-risk disease, demonstrating statistically significant improvement in disease-free survival. The company received Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA in May 2025 and plans to submit a Biologics License Application in the fourth quarter of 2026. Aglatimagene is also being evaluated in phase 2a trials for non-small cell lung cancer and pancreatic cancer.
Linoserpaturev, the company's lead HSV-based candidate, is being evaluated in an investigator-sponsored phase 1b trial for recurrent high-grade glioma. In October 2023, Candel published results in Nature demonstrating extended overall survival associated with immune activation in treated patients.
Candel also developed the enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was incorporated in Delaware in 2003 and completed its initial public offering in July 2021. Candel currently owns development and commercialization rights for all programs in major markets including the United States, Europe, and Asia.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- NEEDHAM, MA
- Fiscal year end
- December
- CIK
- 1841387
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Candel Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Candel Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Candel Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Candel Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Candel Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”